Ozone Therapy https://www.pagepressjournals.org/index.php/ozone <p><strong>Ozone Therapy</strong> intends to be the accessible and innovative leading edge interdisciplinary journal for the ozone-therapy practitioners worldwide, by publishing in different languages to be easier referred to and by establishing its own source of scientific information. <strong>Ozone Therapy</strong> seeks to publish peer-reviewed, original manuscripts dedicated to oxygen-ozone therapy; innovative observational works to open new therapeutic frontiers and study/verification scientific papers regarding known and registered applications;&nbsp;interdisciplinary papers devoted to other disciplines (e.g. Management, Finance, Healthcare) connected with the use of ozone in different fields.</p> <p><strong>Ozone Therapy</strong>&nbsp;is published under the auspices of the SIOOT (Italian Society for Oxygen-Ozone Therapy).</p> PAGEPress Scientific Publications, Pavia, Italy en-US Ozone Therapy 2499-5169 <p><strong>PAGEPress</strong> has chosen to apply the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener"><strong>Creative Commons Attribution NonCommercial 4.0 International License</strong></a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.<br><br> An Open Access Publication is one that meets the following two conditions:</p> <ol> <li>the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li> <li>a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li> </ol> <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</li> </ol> Ozone therapy in 40 patients with fibromyalgia: an effective therapy https://www.pagepressjournals.org/index.php/ozone/article/view/7969 <p>Fibromyalgia is a chronic disorder with a very complex symptomatology. There is evidence that oxidative stress is increased in fibromyalgia, although it is not known whether this increase is involved as a causative factor in the development of the disease, or whether it is secondary to the patients’ unfit condition. Ozone therapy is thought to act by exerting a mild, transient, and controlled oxidative stress that promotes an up regulation of the antioxidant system and a modulation of the immune system. The objective of the present study was to get a preliminary evaluation of the potential effectiveness of ozone therapy in the management of fibromyalgia. At our knowledge, this is the largest study of patients with fibromyalgia treated with ozone therapy reported in the literature and it demonstrates that the ozone therapy is an effective treatment for fibromyalgia patients without significant side effects.</p> Umberto Tirelli Cinzia Cirrito Martina Pavanello ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-12-18 2018-12-18 3 3 10.4081/ozone.2018.7969 Microbiological aspects of ozone: bactericidal activity and antibiotic/antimicrobial resistance in bacterial strains treated with ozone https://www.pagepressjournals.org/index.php/ozone/article/view/7971 <p>Antimicrobial resistance is one of the most complex global health challenges today. The world has long ignored warnings that antibiotics and other medicines are losing their effectiveness after decades of overuse and misuse in human medicine, animal health and agriculture. Common illnesses like pneumonia, postoperative infections, diarrhoeal and sexually transmitted diseases, as well as the world’s largest infectious disease killers – tuberculosis (TB), HIV and malaria – are increasingly becoming untreatable because of the emergence and spread of drug resistance. Worsening antimicrobial resistance could have serious public health, economic and social implications. The threat of antimicrobial resistance is also becoming a key consideration for programmes addressing maternal and child health, sexual and reproductive health, foodborne diseases, water and sanitation, and infection prevention and control. Although the 21st century is being shaped by technology and innovation, humans could soon find themselves in an era where simple infections once again kill millions every year. The past three years have seen unprecedented global political momentum to address antimicrobial resistance: in 2015, governments adopted a global action plan at the World Health Assembly and in 2016 passed a political declaration at the United Nations General Assembly. Antimicrobial resistance has made it onto the agendas of the G7 and G20 groups and is a core component of the Global Health Security Agenda. WHO is working closely with the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health in leading global efforts against antimicrobial resistance and ensuring that the necessary momentum is consolidated and sustained. These efforts are guided by an ad-hoc interagency coordination group established in 2017. A global development and stewardship framework to combat antimicrobial resistance is being drafted to support the development of new antimicrobial medicines, diagnostics, vaccines and other tools. One of the gravest global concerns about antimicrobial resistance currently is that antibiotic resistance has emerged in so many pathogens, including TB. In 2016, at the high-level meeting of the UN General Assembly on antimicrobial resistance, Heads of State directed an unprecedented level of attention to curbing the spread of infections that are resistant to antimicrobial medicines. They reaffirmed their commitment to stopping the misuse of antimicrobial medicines in human health, animal health and agriculture, and recognized the need for stronger systems to monitor drug-resistant infections and the amounts of antimicrobials used in humans and animals. In the wake of the increasing global awareness of the need for new antibiotics, Member States highlighted market failures, and called for new incentives for investment in research and development of new, effective and affordable medicines, rapid diagnostic tests, and other important therapies to replace those that are losing their effectiveness. In response to this and in line with the Global Action Plan on Antimicrobial Resistance to support the identification of pathogens of greatest concern, WHO developed a priority list of antibiotic resistant bacteria to underpin renewed efforts for the research and development of new antibiotics. The only possible defence against the threat of antimicrobial resistance and the (very real) possibility of a post-antibiotic era is a global and coordinated effort by all stakeholders to support other important therapies such as the Oxygen-Ozone (O2O3) therapy. As a result, the scope and focus of the work underlying this dissertation was to study the application of O2O3 therapy towards several resistant bacteria. Moreover, we evaluated three different framework for gut bacteria, skin and soft tissue infections and mucosal infections.</p> Giuseppe Giuliani Giovanni Ricevuti Antonio Galoforo Marianno Franzini ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-12-18 2018-12-18 3 3 10.4081/ozone.2018.7971 Oxygen-ozone therapy in dentistry: current applications and future prospects https://www.pagepressjournals.org/index.php/ozone/article/view/7968 <p>Starting from 2012, the dental research community began to assess the benefits of oxygen-ozone on human metabolism, for its immune-stimulant and anti-hypoxic action, the increase in protein biosynthesis and activation of angiogenesis. We report the case of a 69-year-old patient, for whom oxygenozone therapy was used as a treatment that could reduce the bone resorption of the alveolar ridges, considering the reduced state of hypoxia resulting therefrom, the improved neoangiogenesis and the positive effect on bone metabolism. The results exceeded our greatest expectations, given that the measurements even showed an increase in bone peaks.</p> Antonello Pulga ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-12-18 2018-12-18 3 3 10.4081/ozone.2018.7968 Effects of oxygen-ozone therapy in the Roth syndrome: a case report https://www.pagepressjournals.org/index.php/ozone/article/view/7970 <p>Meralgia paresthetica (MP) is a disesthetic and/or anesthetic syndrome in the distribution of the lateral femoral cutaneous nerve. It is a compressive or traumatic mononeuropathy, characterized by burning pain and/or discomfort in the anterolateral thigh, without motor or muscle strength changes, with preserved reflexes. The authors report the case of a 52-year-old male with a history of low back pain presented from two-year sensory dysesthesias and paresthesias in the right anterolateral thigh, consistent with meralgia paresthetica; they also describe the first reported use of O2-O3 therapy to relieve the intractable pain associated with MP.</p> Alfredo Romeo Carolina Baiano Marianna Chierchia Francesco Scandone ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-12-18 2018-12-18 3 3 10.4081/ozone.2018.7970